Small issuance possible. Won't move ratings.
• Merck KGaA generates EUR 6bn EBITDA.
• The total cost including Milestones is $3bn or €2.6bn ~0.4x
• The upfront cost was not broken out in the press release from Valo but we would assume something like 75% which would give a ~0.3x increase in leverage.
• Merck KGaA has €2.9bn in cash and generates FCF of ~€2.5bn per year so there may be small issuance to fund the deal but will not move ratings.
• S&P have had a mid-A rating since 2013. The last big acquisitions were Sigma-Aldrich in 2015 which saw leverage go to 3.5x and Versum in 2019 which saw 2.8x. Net leverage is just 1.7x currently.
Find more articles and bullets on these widgets: